OTC Markets OTCPK - Delayed Quote USD

HLS Therapeutics Inc. (HLTRF)

3.4400

0.0000

(0.00%)

At close: May 2 at 4:00:00 PM EDT

HLS Therapeutics to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Brian Walsh, Chief Commercial Officer, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference, which takes place May 5-6, 2025 at the Metro Toronto Convention Centre, in downtown Toronto.

CNW Group 6 days ago

HLTRF
0.00%
HLS Therapeutics to Host Q1 2025 Financial Results Conference Call

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2025 financial results on Thursday, May 8, 2025. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Craig Millian, Chief Executive Officer; John Hanna, Chief Financial Officer; and Brian Walsh, Chief Commercial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.

CNW Group 10 days ago

HLTRF
0.00%
HLS Therapeutics Inc.'s (TSE:HLS) biggest owners are individual investors who got richer after stock soared 18% last week

Key Insights Significant control over HLS Therapeutics by individual investors implies that the general public has more...

Simply Wall St. last month

HLTRF
0.00%
HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and twelve months ended December 31, 2024. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.

CNW Group last month

HLTRF
0.00%
HLS Therapeutics Appoints Christine Elliott to its Board of Directors

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Christine Elliott has been appointed to the Company's Board of Directors (the "Board"), effective immediately.

CNW Group last month

HLTRF
0.00%
HLS Therapeutics to Host Fiscal 2024 Financial Results Conference Call

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2024 financial results on Thursday, March 13, 2025. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Craig Millian, Chief Executive Officer; John Hanna, Chief Financial Officer; and Brian Walsh, Chief Commercial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.

CNW Group 2 months ago

HLTRF
0.00%
Positive Signs As Multiple Insiders Buy HLS Therapeutics Stock

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. 2 months ago

HLTRF
0.00%
HLS Therapeutics (TSE:HLS) investors are sitting on a loss of 83% if they invested five years ago

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...

Simply Wall St. 3 months ago

HLTRF
0.00%
HLS Therapeutics Third Quarter 2024 Earnings: Misses Expectations

HLS Therapeutics ( TSE:HLS ) Third Quarter 2024 Results Key Financial Results Revenue: US$14.1m (down 12% from 3Q...

Simply Wall St. 5 months ago

HLTRF
0.00%
HLS Therapeutics Announces Q3 2024 Financial Results

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and nine months ended September 30, 2024. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.

CNW Group 5 months ago

HLTRF
0.00%
HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 fiscal 2024 financial results on Thursday, November 7, 2024. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer, and Mr. John Hanna, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.

CNW Group 6 months ago

HLTRF
0.00%
HLS Therapeutics Inc. (TSE:HLS) Shares Could Be 38% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, HLS Therapeutics fair value estimate is CA$6.45 Current share...

Simply Wall St. 6 months ago

HLTRF
0.00%
HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Craig Millian, Chief Executive Officer, will present at H.C. Wainwright's 26th Annual Global Investment Conference, which takes place September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.

CNW Group 8 months ago

HLTRF
0.00%
HLS Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line

HLS Therapeutics ( TSE:HLS ) Second Quarter 2024 Results Key Financial Results Revenue: US$14.5m (down 12% from 2Q...

Simply Wall St. 8 months ago

HLTRF
0.00%
HLS Therapeutics Announces Q2 2024 Financial Results

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and six months ended June 30, 2024. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.

CNW Group 8 months ago

HLTRF
0.00%
HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement ("PLA") with the province of Alberta, for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with Alberta Health is effective August 1, 2024.

CNW Group 9 months ago

HLTRF
0.00%
HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 fiscal 2024 financial results on Thursday, August 8, 2024. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr. John Hanna, Interim Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.

CNW Group 9 months ago

HLTRF
0.00%
HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has sold its royalty interest and milestone payment obligations in the global sales of XENPOZYME (olipudase alfa) to DRI Healthcare Trust ("DRI Healthcare"), effective June 28, 2024. All dollar amounts are in U.S. dollars, unless otherwise stated.

CNW Group 9 months ago

HLTRF
0.00%
HLS Therapeutics Reports Annual Meeting Results

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 7, 2024.

CNW Group 10 months ago

HLTRF
0.00%
Shareholders in HLS Therapeutics (TSE:HLS) are in the red if they invested three years ago

Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So...

Simply Wall St. 10 months ago

HLTRF
0.00%

Performance Overview

Return	HLTRF	S&P/TSX Composite index (^GSPTSE)
YTD	+27.88%	+1.67%
1-Year	-3.37%	+14.70%
3-Year	-67.65%	+20.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

HLS Therapeutics Inc. (HLTRF)

HLS Therapeutics to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

HLS Therapeutics to Host Q1 2025 Financial Results Conference Call

HLS Therapeutics Inc.'s (TSE:HLS) biggest owners are individual investors who got richer after stock soared 18% last week

HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid

HLS Therapeutics Appoints Christine Elliott to its Board of Directors

HLS Therapeutics to Host Fiscal 2024 Financial Results Conference Call

Positive Signs As Multiple Insiders Buy HLS Therapeutics Stock

HLS Therapeutics (TSE:HLS) investors are sitting on a loss of 83% if they invested five years ago

HLS Therapeutics Third Quarter 2024 Earnings: Misses Expectations

HLS Therapeutics Announces Q3 2024 Financial Results

HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call

HLS Therapeutics Inc. (TSE:HLS) Shares Could Be 38% Below Their Intrinsic Value Estimate

HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference

HLS Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line

HLS Therapeutics Announces Q2 2024 Financial Results

HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan

HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call

HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust

HLS Therapeutics Reports Annual Meeting Results

Shareholders in HLS Therapeutics (TSE:HLS) are in the red if they invested three years ago

Performance Overview